Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

September 18, 2025 8:00 AM

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of cancer, aging, and age-related diseases, today announced new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of the KDM5 histone demethylase family.Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors and activate...

Read more

Seven Starling Raises Fresh Funding to Accelerate National Expansion of Women's Mental Health Platform

September 18, 2025 8:00 AM

Seven Starling, a leading virtual provider of women's behavioral health services, today announced it has raised $8M in funding led by Rethink Impact to accelerate national expansion of its specialized maternal mental health platform. The round includes participation from insiders Pear VC, Zeal Capital Partners, Magnify Ventures, Ulu Ventures, Expa, Fiore Ventures, the March of Dimes, Rogue Women's Fund, and Graham & Walker.Currently operating in...

Read more

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

September 18, 2025 7:30 AM

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and disruptive therapeutics assets, is pleased to announce that it has entered into a purchase agreement (the "Purchase Agreement") with YA II PL, Ltd. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP, pursuant to which the Company has issued and Yorkville has...

Read more

Dr. Meegan Gruber Awarded Best Plastic Surgeons in America by Newsweek

September 18, 2025 7:00 AM

The America's Best Plastic Surgeons in America 2025 list from Newsweek and Statista includes Dr. Meegan Gruber, MD, of Gruber Plastic Surgery for her expertise in liposuction procedures.The designation results from peer selection and quality weighting because American surgeons and medical professionals conduct evaluations to establish the worth of each other's work. Dr. Gruber maintains dual board certification as a plastic surgeon and runs her...

Read more

Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents

September 18, 2025 6:30 AM

Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the issuance of four additional U.S. patents protecting its TRUVIEW and TRUFORMA diagnostic platforms.These new patents significantly strengthen Zomedica's intellectual property portfolio and enhance the Company's ability to compete and...

Read more

Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection

September 18, 2025 5:00 AM

Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) ("Skinvisible") to leverage patent-pending Invisicare® topical and transdermal cannabis developments in the obesity market. The agreement will enhance the strategic partnership for innovative cannabinoid delivery technology with new developments and patent protection....

Read more

David Banach of Woodbridge, CT Calls for Stronger Community Action on Infection Prevention

September 17, 2025 10:15 AM

David Banach of Woodbridge, CT is raising awareness about the critical importance of infection prevention, calling on communities to take proactive steps to protect themselves and others. Drawing on nearly two decades of clinical practice, teaching, and research, Banach emphasizes that small actions by individuals can create lasting impacts for public health."Infection prevention is about systems, but systems are built by people," Banach...

Read more

DistillerSR Launches First-of-Its-Kind Agentic AI Capabilities to Eliminate Evidence Silos and Accelerate Time to Market

September 17, 2025 10:00 AM

DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced the launch of DistillerSR Agentic AI. The first-of-its-kind capability combines DistillerSR trusted, expertly curated literature evidence with Agentic AI, enabling research teams and business leaders to access a validated, organization-wide source of evidence. With improved time to insight and more aligned decision-making,...

Read more

NCQA Names Dr. Vivek Garg as President and Chief Executive Officer

September 17, 2025 9:15 AM

The National Committee for Quality Assurance (NCQA) today announced that Vivek Garg, MD, MBA, will become its next President and Chief Executive Officer, effective January 5, 2026. Dr. Garg succeeds NCQA founder and current President Margaret E. O'Kane, who will retire at the end of this year after more than three decades of leadership.Dr. Garg currently serves as Chief Medical Officer for CenterWell Senior Primary Care, part of Humana, where he...

Read more

Ardent Health Announces Enterprise Rollout of Ambience Healthcare's AI Platform for Documentation, Coding and Clinical Workflows

September 17, 2025 9:05 AM

Ardent Health, a leading provider of healthcare in growing mid-sized urban communities across the U.S., has partnered with Ambience Healthcare to launch an enterprise-wide deployment of its AI platform across Ardent's ambulatory network.Ardent clinicians now have access to Ambience's AI platform to generate comprehensive and compliant documentation, reduce burnout, and enhance high-quality care delivery. This expansion follows a high-performing...

Read more

Keensight Capital Acquires Majority Stake in Isto Biologics, a Leading Orthobiologics Player, from Thompson Street Capital Partners

September 17, 2025 9:00 AM

Founded in 2016, Isto Biologics is a regenerative MedTech company developing and manufacturing orthobiologic products to help patients heal faster. Isto's best-in-class product offering covers six functional areas of unique bone graft solutions, and includes a range of allografts, which are notably used for bone repair in the spine. Isto sells its products to more than 400 hospitals and clinics, which are used in 15,000 surgical procedures per...

Read more

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

September 17, 2025 8:30 AM

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced it has launched its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ pre-workout product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual...

Read more

Rancho Biosciences Expands Leadership in Biomedical Ontology With Appointment of Dr. Jane Lomax

September 17, 2025 8:00 AM

Rancho Biosciences, most trusted partner for scientific data services for the life sciences industry, today announced the appointment of Dr. Jane Lomax as Head of Terminology Services. A globally respected leader in the field of biomedical ontology, Dr. Lomax brings decades of experience guiding ontology strategy, development, and governance for high-impact initiatives across pharma, academia, and global data consortia.Most recently, Dr. Lomax...

Read more

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

September 17, 2025 8:00 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis. These data are being presented at the 2025 European Academy of Dermatology and...

Read more

Omni-Biotic US Expands Into Children's Gut Health With Two New Probiotics: AB 10 Kids and Stress Release Kids

September 17, 2025 8:00 AM

Omni-Biotic US, the company that introduced Europe's leading probiotic brand to the United States, is proud to announce the launch of two breakthrough probiotics for children: Omni-Biotic AB 10 Kids and Omni-Biotic Stress Release Kids. These new formulations adapt Omni-Biotic's award-winning adult probiotics into gentle, child-friendly formats, giving parents science-backed solutions to support their children's gut health, immunity, and...

Read more

Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center

September 17, 2025 7:35 AM

Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) today announces that the U.S. Department of Defense has awarded a contract to supply the TetraGraph® system to all major operating rooms at Walter Reed National Military Medical Center in Bethesda, Maryland. The installation furhter includes an expected annual purchase volume exceeding 5,000 TetraSens® sensors.Walter Reed is the world's largest multiservice military hospital and a key part of the...

Read more

Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety

September 17, 2025 2:00 AM

Hemogenyx Pharmaceuticals plc is pleased to announce that the third patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in adults.The treatment was well tolerated and met the trial's predefined initial safety criteria. Importantly, early indications of clinical efficacy have been...

Read more

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

September 17, 2025 1:00 AM

Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARI™ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 being held in Paris, France, from September 17-20th.Details...

Read more

Optigenex Inc. Reports Positive Results in a Group of Human Subjects with Normal Cognitive Function, in a Double-Blind, Cross Over, Placebo Controlled, Randomized Cognitive Study with ac-11(R)

September 16, 2025 6:55 PM

Optigenex announced today results from daily oral intake of ac-11®. The data demonstrates statistically significant improvement in attention, memory and executive function. Additionally, 64 percent of the participants evidenced improvement in social cognition. Social cognition refers to a complex set of mental abilities underlying social stimulus perception, processing, interpretation and response. Improvement in attention and focus was the most...

Read more

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

September 16, 2025 4:05 PM

Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on Tuesday, September 23, 2025. The Company has scheduled a conference call and webcast that same day,...

Read more